The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Anti-Asthmatics And COPD Drugs Market In 2026 And What Value Is Projected For 2030?
The anti-asthmatics and copd drugs market size has demonstrated consistent expansion in recent years. This market is anticipated to increase from $85.08 billion in 2025 to $89.13 billion in 2026, registering a compound annual growth rate (CAGR) of 4.8%. The market’s past growth can be ascribed to elements such as the growing occurrence of asthma and copd, elevated levels of smoking and air pollution, inadequate knowledge regarding preventive therapies, the broad accessibility of generic bronchodilators, and the development of hospital pharmacy networks.
The anti-asthmatics and COPD drugs market size is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $111.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.7%. This expansion during the projection period can be attributed to several factors, including breakthroughs in biologics and monoclonal antibodies, the incorporation of AI into treatment strategies, the rising embrace of digital health technologies, the broadening of online pharmacy platforms, and the creation of specialized therapies for severe COPD. Key trends expected within this period encompass individualized asthma care, remote patient monitoring and telemedicine, the emergence of inhalable biologics, a rising preference for combined therapeutic approaches, and an emphasis on formulations tailored for pediatric and geriatric patients.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What Key Drivers Are Influencing The Growth Of The Anti-Asthmatics And COPD Drugs Market?
The widespread occurrence of asthmatic conditions is anticipated to boost the anti-asthmatics and COPD drugs market in the future. Asthma is characterized as a chronic illness marked by inflammation and swelling in the airways, leading to their constriction and impeding airflow from the nose and mouth to the lungs. The rising incidence of asthma has stimulated a significant rise in the discovery of novel anti-asthmatics and COPD drugs designed to manage asthmatic conditions. As an illustration, Official Statistics, a UK government department, reported in June 2025 that emergency admissions for asthma among adults (19+) rose by 17% in the financial year ending 2024, relative to the preceding year. Consequently, the growing prevalence of asthmatic disorders is fostering an uptick in the creation of new medications, which will, in turn, further propel the asthma drug market.
What Are The Key Segments Of The Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
What Key Trends Are Influencing The Development Of The Anti-Asthmatics And COPD Drugs Market?
Leading companies operating within the anti-asthmatics and COPD drugs market are prioritizing technological advancements, such as next-generation propellant inhalers, to satisfy the growing demand for environmentally sustainable and patient-friendly respiratory treatments. This advanced propellant technology replaces traditional hydrofluoroalkane (HFA) propellants with alternatives that have a near-zero Global Warming Potential (GWP), effectively reducing the carbon footprint of pressurized metered-dose inhalers (pMDIs) while maintaining their efficiency in drug delivery. For example, in May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, introduced Trixeo Aerosphere, an innovative fixed-dose triple-combination therapy for COPD comprising budesonide, glycopyrronium, and formoterol fumarate, now delivered via a next-generation propellant. This pMDI guarantees bioequivalence to earlier formulations, preserves its established safety and efficacy profile, and offers a 99.9% reduction in GWP compared to traditional propellants. Trixeo Aerosphere supports sustainable healthcare practices without compromising clinical outcomes, providing an effective, low-carbon-footprint solution for patients requiring inhaled respiratory therapy.
Who Are The Leading Companies Operating In The Anti-Asthmatics And COPD Drugs Market?
Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.
Read the full anti-asthmatics and copd drugs market report here:
Which Region Is Expected To Register The Fastest Growth In The Anti-Asthmatics And COPD Drugs Market?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Asthmatics And COPD Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp
Browse Through More Reports Similar to the Global Anti-Asthmatics And COPD Drugs Market 2026, By The Business Research Company
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Asthma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model